Nisa Investment Advisors LLC Sells 6,352 Shares of Humana Inc. $HUM

Nisa Investment Advisors LLC lessened its stake in Humana Inc. (NYSE:HUM) by 19.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,990 shares of the insurance provider’s stock after selling 6,352 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Humana were worth $6,623,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Cary Street Partners Investment Advisory LLC increased its holdings in Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after buying an additional 46 shares during the period. Zions Bancorporation National Association UT bought a new position in Humana in the first quarter valued at approximately $37,000. CVA Family Office LLC raised its position in Humana by 63.4% during the second quarter. CVA Family Office LLC now owns 219 shares of the insurance provider’s stock valued at $54,000 after purchasing an additional 85 shares in the last quarter. Ransom Advisory Ltd acquired a new position in Humana during the first quarter valued at approximately $66,000. Finally, Transamerica Financial Advisors LLC lifted its stake in Humana by 1,027.6% during the first quarter. Transamerica Financial Advisors LLC now owns 327 shares of the insurance provider’s stock worth $87,000 after purchasing an additional 298 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

NYSE:HUM opened at $295.02 on Wednesday. The stock’s 50-day moving average is $281.89 and its 200-day moving average is $258.87. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $315.35. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The stock has a market cap of $35.48 billion, a P/E ratio of 22.64, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The business had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. During the same quarter in the prior year, the business earned $6.96 earnings per share. The firm’s quarterly revenue was up 9.6% on a year-over-year basis. Equities research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Friday, December 26th. Humana’s payout ratio is 27.17%.

Wall Street Analysts Forecast Growth

HUM has been the topic of several recent analyst reports. Robert W. Baird decreased their price target on Humana from $300.00 to $297.00 and set a “neutral” rating on the stock in a research note on Friday, July 25th. Mizuho lifted their target price on Humana from $300.00 to $345.00 and gave the company an “outperform” rating in a research report on Thursday, October 9th. Bank of America increased their target price on shares of Humana from $280.00 to $300.00 and gave the stock a “neutral” rating in a report on Friday, October 10th. Wolfe Research raised their price target on shares of Humana from $283.00 to $313.00 and gave the company an “outperform” rating in a research note on Monday, October 6th. Finally, Sanford C. Bernstein upped their price objective on shares of Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Humana has an average rating of “Hold” and an average target price of $297.58.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.